바로가기 및 건너띄기 링크
본문 바로가기
주메뉴 바로가기

뉴스레터

home > 자료실> 뉴스레터

글자크기

Seoul to spend 1 tln won for development of new medicines-Issue 3 (Oct. 2011)

Seoul to spend 1 tln won for development of new medicines-Issue 3 (Oct. 2011) : 작성자, 작성일, 조회수, 정보 제공
작성자 관리자
작성일 2011-10-01 조회수 795
media
media

Issue 3 (Oct. 2011)

Views 462 Votes 0 2011.10.13 16:36:43
bg.jpg
htlogo_01.jpg
htlogo_02.jpg
Issue 3 (Oct. 2011)
htlogo_04.jpg
HT Korea News
line.jpg
Ground for Bio Industry to Launch in Korea
Ground for Bio Industry to Launch in Korea
The biggest international event held in Korea for domestic pharmaceutical and bio industry, 'Bio Korea 2011' has kicked off at COEX on 28. Korea Health Industry Development Institute(director Ko, Kyung-hwa) called a grand opening....more
Hanwha and Minnesota look for new business
Hanwha and Minnesota look for new business
Hanwha Group Chairman Kim Seung-youn met Mark Dayton, the governor of the U.S. state of Minnesota, yesterday. The talks centered on ways of enhancing bilateral cooperation in solar energy, new renewable energy sources and biological drug development.Dayton's delegation of 35 people, including politicians....more
Seoul to spend 1 tln won for development of new medicines
Seoul to spend 1 tln won for development of new medicines
SEOUL, Sept. 20 (Yonhap) -- South Korea on Tuesday said it will spend 1 trillion won (US$877 million) by 2020 to help local pharmaceutical firms develop new drugs. As an initial step, the government launched a new committee to oversee the support project. The committee consists of officials from three government ministries -- the Ministry of Health and Welfare, the Ministry of Knowledge Economy and the Ministry of Education, Science and Technology...more
SK biopharmaceuticals Enters into a Collaboration Agreement to Study Lou Gehrig's Disease
SK biopharmaceuticals Enters into a Collaboration Agreement to Study Lou Gehrig's Disease
SEOUL, Korea & JACKSONVILLE, Fla., Sep 19, 2011 (BUSINESS WIRE) -- South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs...more
Samsung - The next big bet
Samsung - The next big bet
IN 2000 Samsung started making batteries for digital gadgets. Ten years later it sold more of them than any other company in the world. In 2001 it threw resources into flat-panel televisions. Within four years it was the market leader. In 2002 the...more
Emerson Selected to Automate Korean Arthritis Drug Facility
Emerson Selected to Automate Korean Arthritis Drug Facility
Hanwha Chemical has selected EEmerson Process Management to supply and commission its DeltaV digital automation system for a pharmaceutical production facility in Osong Bio-technology Technopolis, Chungcheongbuk-do, Korea. Known as the Eagle Project, the facility will manufacture Hanwha's biosimilar ...more
Columbus Pioneers News
line.jpg
Dong-A Pharmaceutical
line_01.jpg
Everland-Samsung Elec to Invest W90b in Biologics
Dong-A Pharm. to Build Biosimilar Plant in Songdo
South Korea's No.1 pharmaceutical company Dong-A Pharm. will advance into the biosimilar market. Biosimilars refer to subsequent versions of biopharmaceutical products following patent and exclusivity expiry on the products. Dong-A Pharm. announced on Thursday that it signed a Memorandum of Understanding.... more
Medipost
line_01.jpg
Medipost aims to dominate global biopharmaceutical industry
Medipost aims to dominate global biopharmaceutical industry
Unlike other many bio venture companies that suffered from the fallout of the scandal, Medipost was able to keep a strong position in stem cell research and has taken the lead in the cord blood industry. Behind the survival and enduring success is Yang Yoon-sun, the founder and chief executive officer of Medipost. She has ...more
Medi-Future
line_01.jpg
MEDI-FUTURE, Inc., Starts First Sales of “Dedicated Breast MRI System” in Domestic Market
MEDI-FUTURE, Inc., Starts First Sales of "Dedicated Breast MRI System" in Domestic Market
MEDI-FUTURE, Inc. (CEO Joseph Lee), Korea's only dedicated women's healthcare company, revealed on Aug. 2nd, that the company will be the exclusive distributor of 'Dedicated Breast MRI System' for the first time in domestic market...more
Korea Health Industry Development Institute USA Office,
420 Lexington Ave., Suite 2546, New York, NY 10170
T. 646.783.6090 F.646.783.6099
Email : info@khidiusa.org If you are no longer interested you can unsubscribe instantly
logo_01.jpg logo_02.jpg

댓글등록

로그인 또는 본인확인 후 작성 가능합니다.

0/250

의견입력영역